Trinity Biotech director reports ADS, option stakes
Trinity Biotech plc director Ronan O'Caoimh has filed an initial ownership report showing significant direct stakes in the company.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
3
Rhea-AI Filing Summary
Trinity Biotech plc director Ronan O'Caoimh has filed an initial ownership report showing significant direct stakes in the company. He reports holding 486,208 ADS as of the filing date. In addition, he holds multiple ADS option awards with exercise prices of $13.70, $14.50, $3.80 and $2.80 per ADS, with expiration dates ranging from 2026 to 2031, providing potential future rights to acquire additional ADS over several years.
Insider Trade Summary
18 transactions reported
Mixed
18 txns
Insider
O'Caoimh Ronan
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | ADS OPTIONS | -- | -- | -- |
| holding | ADS OPTIONS | -- | -- | -- |
| holding | ADS OPTIONS | -- | -- | -- |
| holding | ADS OPTIONS | -- | -- | -- |
| holding | ADS OPTIONS | -- | -- | -- |
| holding | ADS OPTIONS | -- | -- | -- |
| holding | ADS OPTIONS | -- | -- | -- |
| holding | ADS OPTIONS | -- | -- | -- |
| holding | ADS OPTIONS | -- | -- | -- |
| holding | ADS OPTIONS | -- | -- | -- |
| holding | ADS OPTIONS | -- | -- | -- |
| holding | ADS OPTIONS | -- | -- | -- |
| holding | ADS OPTIONS | -- | -- | -- |
| holding | ADS OPTIONS | -- | -- | -- |
| holding | ADS OPTIONS | -- | -- | -- |
| holding | ADS OPTIONS | -- | -- | -- |
| holding | ADS OPTIONS | -- | -- | -- |
| holding | ADS | -- | -- | -- |
Holdings After Transaction:
ADS OPTIONS — 409,671 contracts (Direct);
ADS — 486,208 shares (Direct)
Key Figures
Direct ADS holdings: 486,208 ADS
Option strike price: $13.70 per ADS
Option strike price: $14.50 per ADS
+5 more
8 metrics
Direct ADS holdings
486,208 ADS
Total ADS directly owned as of Form 3
Option strike price
$13.70 per ADS
ADS options with $13.70 exercise price expiring 2026-06-14
Option strike price
$14.50 per ADS
ADS options with $14.50 exercise price expiring 2027-11-17
Option strike price
$3.80 per ADS
ADS options with $3.80 exercise price expiring 2027-03-20
Option strike price
$2.80 per ADS
ADS options with $2.80 exercise price expiring 2031-02-02
Underlying option shares
101,500 ADS options
One ADS option position with 101,500 underlying shares at $13.70
Underlying option shares
60,000 ADS options
One ADS option position with 60,000 underlying shares at $14.50
Underlying option shares
16,667 ADS options
One ADS option position with 16,667 underlying shares at $3.80
Key Terms
ADS, ADS OPTIONS, exercise price, expiration date, +1 more
5 terms
ADS financial
"security_title: "ADS" in the holding entry for 486,208.0000"
Ads are paid promotional messages a company places across media — online, on TV, in print, or on social platforms — to attract customers, explain products, or shape public perception. For investors, ads matter because they drive sales growth, affect how much a company must spend to win customers, and influence brand strength and long-term value. Ads can also create regulatory or reputational risk if claims are misleading, which can affect profits and stock price.
ADS OPTIONS financial
"security_title: "ADS OPTIONS" across multiple option award entries"
exercise price financial
"conversion_or_exercise_price fields such as "13.7000" and "2.8000""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date fields such as "2026-06-14T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the Form 3 filing by Ronan O'Caoimh at TRIB show?
The Form 3 shows that director Ronan O'Caoimh directly holds 486,208 ADS of Trinity Biotech plc, plus several ADS option grants with future exercise rights at specified prices and expiration dates between 2026 and 2031.
How many Trinity Biotech ADS does Ronan O'Caoimh directly own?
Ronan O'Caoimh directly owns 486,208 ADS of Trinity Biotech plc. This figure reflects his reported beneficial ownership of common equity in ADS form as of the Form 3 filing date for issuer symbol TRIB.
What option positions does the TRIB director report on this Form 3?
The director reports multiple ADS options with exercise prices of $13.70, $14.50, $3.80 and $2.80 per ADS. These options have stated expiration dates between 2026 and 2031, providing long-dated potential to acquire ADS.
Are there buy or sell transactions reported in this TRIB Form 3?
No buy or sell trades are reported. The Form 3 lists holdings only: existing ADS ownership and ADS option awards. It establishes Ronan O'Caoimh’s starting ownership position as a director rather than disclosing new market transactions.
What is the significance of the expiration dates on the TRIB ADS options?
The ADS options expire between 2026 and 2031, defining how long Ronan O'Caoimh can exercise them at set prices. Later expiration dates, such as 2031-02-02, indicate longer-term potential to increase his ADS holdings if exercised.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates